Cargando…

Preference for biological motion is reduced in ASD: implications for clinical trials and the search for biomarkers

BACKGROUND: The neurocognitive mechanisms underlying autism spectrum disorder (ASD) remain unclear. Progress has been largely hampered by small sample sizes, variable age ranges and resulting inconsistent findings. There is a pressing need for large definitive studies to delineate the nature and ext...

Descripción completa

Detalles Bibliográficos
Autores principales: Mason, L., Shic, F., Falck-Ytter, T., Chakrabarti, B., Charman, T., Loth, E., Tillmann, J., Banaschewski, T., Baron-Cohen, S., Bölte, S., Buitelaar, J., Durston, S., Oranje, B., Persico, A. M., Beckmann, C., Bougeron, T., Dell’Acqua, F., Ecker, C., Moessnang, C., Murphy, D., Johnson, M. H., Jones, E. J. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672507/
https://www.ncbi.nlm.nih.gov/pubmed/34911565
http://dx.doi.org/10.1186/s13229-021-00476-0
_version_ 1784615368346566656
author Mason, L.
Shic, F.
Falck-Ytter, T.
Chakrabarti, B.
Charman, T.
Loth, E.
Tillmann, J.
Banaschewski, T.
Baron-Cohen, S.
Bölte, S.
Buitelaar, J.
Durston, S.
Oranje, B.
Persico, A. M.
Beckmann, C.
Bougeron, T.
Dell’Acqua, F.
Ecker, C.
Moessnang, C.
Murphy, D.
Johnson, M. H.
Jones, E. J. H.
author_facet Mason, L.
Shic, F.
Falck-Ytter, T.
Chakrabarti, B.
Charman, T.
Loth, E.
Tillmann, J.
Banaschewski, T.
Baron-Cohen, S.
Bölte, S.
Buitelaar, J.
Durston, S.
Oranje, B.
Persico, A. M.
Beckmann, C.
Bougeron, T.
Dell’Acqua, F.
Ecker, C.
Moessnang, C.
Murphy, D.
Johnson, M. H.
Jones, E. J. H.
author_sort Mason, L.
collection PubMed
description BACKGROUND: The neurocognitive mechanisms underlying autism spectrum disorder (ASD) remain unclear. Progress has been largely hampered by small sample sizes, variable age ranges and resulting inconsistent findings. There is a pressing need for large definitive studies to delineate the nature and extent of key case/control differences to direct research towards fruitful areas for future investigation. Here we focus on perception of biological motion, a promising index of social brain function which may be altered in ASD. In a large sample ranging from childhood to adulthood, we assess whether biological motion preference differs in ASD compared to neurotypical participants (NT), how differences are modulated by age and sex and whether they are associated with dimensional variation in concurrent or later symptomatology. METHODS: Eye-tracking data were collected from 486 6-to-30-year-old autistic (N = 282) and non-autistic control (N = 204) participants whilst they viewed 28 trials pairing biological (BM) and control (non-biological, CTRL) motion. Preference for the biological motion stimulus was calculated as (1) proportion looking time difference (BM-CTRL) and (2) peak look duration difference (BM-CTRL). RESULTS: The ASD group showed a present but weaker preference for biological motion than the NT group. The nature of the control stimulus modulated preference for biological motion in both groups. Biological motion preference did not vary with age, gender, or concurrent or prospective social communicative skill within the ASD group, although a lack of clear preference for either stimulus was associated with higher social-communicative symptoms at baseline. LIMITATIONS: The paired visual preference we used may underestimate preference for a stimulus in younger and lower IQ individuals. Our ASD group had a lower average IQ by approximately seven points. 18% of our sample was not analysed for various technical and behavioural reasons. CONCLUSIONS: Biological motion preference elicits small-to-medium-sized case–control effects, but individual differences do not strongly relate to core social autism associated symptomatology. We interpret this as an autistic difference (as opposed to a deficit) likely manifest in social brain regions. The extent to which this is an innate difference present from birth and central to the autistic phenotype, or the consequence of a life lived with ASD, is unclear. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13229-021-00476-0.
format Online
Article
Text
id pubmed-8672507
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86725072021-12-15 Preference for biological motion is reduced in ASD: implications for clinical trials and the search for biomarkers Mason, L. Shic, F. Falck-Ytter, T. Chakrabarti, B. Charman, T. Loth, E. Tillmann, J. Banaschewski, T. Baron-Cohen, S. Bölte, S. Buitelaar, J. Durston, S. Oranje, B. Persico, A. M. Beckmann, C. Bougeron, T. Dell’Acqua, F. Ecker, C. Moessnang, C. Murphy, D. Johnson, M. H. Jones, E. J. H. Mol Autism Research BACKGROUND: The neurocognitive mechanisms underlying autism spectrum disorder (ASD) remain unclear. Progress has been largely hampered by small sample sizes, variable age ranges and resulting inconsistent findings. There is a pressing need for large definitive studies to delineate the nature and extent of key case/control differences to direct research towards fruitful areas for future investigation. Here we focus on perception of biological motion, a promising index of social brain function which may be altered in ASD. In a large sample ranging from childhood to adulthood, we assess whether biological motion preference differs in ASD compared to neurotypical participants (NT), how differences are modulated by age and sex and whether they are associated with dimensional variation in concurrent or later symptomatology. METHODS: Eye-tracking data were collected from 486 6-to-30-year-old autistic (N = 282) and non-autistic control (N = 204) participants whilst they viewed 28 trials pairing biological (BM) and control (non-biological, CTRL) motion. Preference for the biological motion stimulus was calculated as (1) proportion looking time difference (BM-CTRL) and (2) peak look duration difference (BM-CTRL). RESULTS: The ASD group showed a present but weaker preference for biological motion than the NT group. The nature of the control stimulus modulated preference for biological motion in both groups. Biological motion preference did not vary with age, gender, or concurrent or prospective social communicative skill within the ASD group, although a lack of clear preference for either stimulus was associated with higher social-communicative symptoms at baseline. LIMITATIONS: The paired visual preference we used may underestimate preference for a stimulus in younger and lower IQ individuals. Our ASD group had a lower average IQ by approximately seven points. 18% of our sample was not analysed for various technical and behavioural reasons. CONCLUSIONS: Biological motion preference elicits small-to-medium-sized case–control effects, but individual differences do not strongly relate to core social autism associated symptomatology. We interpret this as an autistic difference (as opposed to a deficit) likely manifest in social brain regions. The extent to which this is an innate difference present from birth and central to the autistic phenotype, or the consequence of a life lived with ASD, is unclear. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13229-021-00476-0. BioMed Central 2021-12-15 /pmc/articles/PMC8672507/ /pubmed/34911565 http://dx.doi.org/10.1186/s13229-021-00476-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Mason, L.
Shic, F.
Falck-Ytter, T.
Chakrabarti, B.
Charman, T.
Loth, E.
Tillmann, J.
Banaschewski, T.
Baron-Cohen, S.
Bölte, S.
Buitelaar, J.
Durston, S.
Oranje, B.
Persico, A. M.
Beckmann, C.
Bougeron, T.
Dell’Acqua, F.
Ecker, C.
Moessnang, C.
Murphy, D.
Johnson, M. H.
Jones, E. J. H.
Preference for biological motion is reduced in ASD: implications for clinical trials and the search for biomarkers
title Preference for biological motion is reduced in ASD: implications for clinical trials and the search for biomarkers
title_full Preference for biological motion is reduced in ASD: implications for clinical trials and the search for biomarkers
title_fullStr Preference for biological motion is reduced in ASD: implications for clinical trials and the search for biomarkers
title_full_unstemmed Preference for biological motion is reduced in ASD: implications for clinical trials and the search for biomarkers
title_short Preference for biological motion is reduced in ASD: implications for clinical trials and the search for biomarkers
title_sort preference for biological motion is reduced in asd: implications for clinical trials and the search for biomarkers
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672507/
https://www.ncbi.nlm.nih.gov/pubmed/34911565
http://dx.doi.org/10.1186/s13229-021-00476-0
work_keys_str_mv AT masonl preferenceforbiologicalmotionisreducedinasdimplicationsforclinicaltrialsandthesearchforbiomarkers
AT shicf preferenceforbiologicalmotionisreducedinasdimplicationsforclinicaltrialsandthesearchforbiomarkers
AT falckyttert preferenceforbiologicalmotionisreducedinasdimplicationsforclinicaltrialsandthesearchforbiomarkers
AT chakrabartib preferenceforbiologicalmotionisreducedinasdimplicationsforclinicaltrialsandthesearchforbiomarkers
AT charmant preferenceforbiologicalmotionisreducedinasdimplicationsforclinicaltrialsandthesearchforbiomarkers
AT lothe preferenceforbiologicalmotionisreducedinasdimplicationsforclinicaltrialsandthesearchforbiomarkers
AT tillmannj preferenceforbiologicalmotionisreducedinasdimplicationsforclinicaltrialsandthesearchforbiomarkers
AT banaschewskit preferenceforbiologicalmotionisreducedinasdimplicationsforclinicaltrialsandthesearchforbiomarkers
AT baroncohens preferenceforbiologicalmotionisreducedinasdimplicationsforclinicaltrialsandthesearchforbiomarkers
AT boltes preferenceforbiologicalmotionisreducedinasdimplicationsforclinicaltrialsandthesearchforbiomarkers
AT buitelaarj preferenceforbiologicalmotionisreducedinasdimplicationsforclinicaltrialsandthesearchforbiomarkers
AT durstons preferenceforbiologicalmotionisreducedinasdimplicationsforclinicaltrialsandthesearchforbiomarkers
AT oranjeb preferenceforbiologicalmotionisreducedinasdimplicationsforclinicaltrialsandthesearchforbiomarkers
AT persicoam preferenceforbiologicalmotionisreducedinasdimplicationsforclinicaltrialsandthesearchforbiomarkers
AT beckmannc preferenceforbiologicalmotionisreducedinasdimplicationsforclinicaltrialsandthesearchforbiomarkers
AT bougeront preferenceforbiologicalmotionisreducedinasdimplicationsforclinicaltrialsandthesearchforbiomarkers
AT dellacquaf preferenceforbiologicalmotionisreducedinasdimplicationsforclinicaltrialsandthesearchforbiomarkers
AT eckerc preferenceforbiologicalmotionisreducedinasdimplicationsforclinicaltrialsandthesearchforbiomarkers
AT moessnangc preferenceforbiologicalmotionisreducedinasdimplicationsforclinicaltrialsandthesearchforbiomarkers
AT murphyd preferenceforbiologicalmotionisreducedinasdimplicationsforclinicaltrialsandthesearchforbiomarkers
AT johnsonmh preferenceforbiologicalmotionisreducedinasdimplicationsforclinicaltrialsandthesearchforbiomarkers
AT jonesejh preferenceforbiologicalmotionisreducedinasdimplicationsforclinicaltrialsandthesearchforbiomarkers
AT preferenceforbiologicalmotionisreducedinasdimplicationsforclinicaltrialsandthesearchforbiomarkers